[Antiphospholipid syndrome diagnosis: an update]

Ann Biol Clin (Paris). 2011 Jul-Aug;69(4):411-8. doi: 10.1684/abc.2011.0592.
[Article in French]


The antiphospholipid syndrome (APS) is characterized by arterial and/or venous thrombosis and pregnancy morbidity in association with the persistent presence of autoantibodies called antiphospholipid antibodies (APAs). APAs are a heterogeneous group of circulating autoantibodies that can be detected either by phospholipid-dependent coagulation test for lupus anticoagulant (LA) or ELISA test for anticardiolipin and anti-β2GPI antibodies. In 2006, the revised criteria for the diagnosis of APS introduce the anti-β2GPI antibodies as a new biological criterion and highlight the necessity to increase the interval between two positive APA test from 6 to 12 weeks. However, despite these updated criteria, the diagnosis of APS remains challenging and we proposed here to make an overview of the latest evolution in the diagnosis of this syndrome.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antibodies, Anticardiolipin / blood
  • Antibodies, Antiphospholipid / blood*
  • Antibodies, Antiphospholipid / immunology
  • Anticoagulants / blood
  • Antiphospholipid Syndrome / blood*
  • Antiphospholipid Syndrome / diagnosis*
  • Antiphospholipid Syndrome / immunology
  • Biomarkers / blood
  • Female
  • Humans
  • Lupus Coagulation Inhibitor / blood
  • Predictive Value of Tests
  • Pregnancy
  • Pregnancy Complications, Hematologic / blood
  • Pregnancy Complications, Hematologic / diagnosis
  • Sensitivity and Specificity
  • beta 2-Glycoprotein I / blood


  • Antibodies, Anticardiolipin
  • Antibodies, Antiphospholipid
  • Anticoagulants
  • Biomarkers
  • Lupus Coagulation Inhibitor
  • beta 2-Glycoprotein I